Citius Oncology, Inc. (CTOR)

Citius Oncology Cash Flow Statement

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Sep 30, 2025	Sep 30, 2024	Sep 30, 2023	Dec 31, 2022
Net Income	-42.51	-24.76	-21.15	-12.7	0.38
Depreciation & Amortization	2.29	-	-	-	-
Stock-Based Compensation	11.91	8.32	7.5	1.97	-
Other Adjustments	0.56	1.06	0.58	0.58	-0.49
Change in Receivables	-1.08	-	-	-	-
Changes in Inventories	-5.95	-12.65	-2.13	-	-
Changes in Accounts Payable	1.21	9.52	2.42	1.2	-
Changes in Accrued Expenses	15.34	4.09	-0.26	-0.8	0.03
Changes in Other Operating Activities	4.19	8.92	13.17	9.76	0.04
Operating Cash Flow	-16.68	-5.49	0.13	0	-0.05
Purchases of Intangible Assets	-10.75	-5.75	-5	-	-
Other Investing Activities	-	-	-	-	-67.32
Investing Cash Flow	-10.75	-5.75	-5	-	-67.32
Long-Term Debt Issued	-	-	3.8	-	-
Long-Term Debt Repaid	-	-	-	-	-0.13
Net Long-Term Debt Issued (Repaid)	-	-	3.8	-	-0.13
Issuance of Common Stock	30.23	15.17	-	-	69.36
Net Common Stock Issued (Repurchased)	30.23	15.17	-	-	69.36
Other Financing Activities	-0.08	-	1.07	-	-1.57
Financing Cash Flow	30.06	15.17	4.87	-	67.66
Net Cash Flow	2.63	3.92	0	0	0.29
Free Cash Flow	-16.68	-5.49	0.13	0	-0.05
Free Cash Flow Per Share	-0.20	-0.07	0.00	-	-0.03
Levered Free Cash Flow	-25.44	-14.87	-4.15	-2.54	0.31
Unlevered Free Cash Flow	-27.03	-14.68	-7.95	-2.54	-0.07

Updated May 15, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q